XBI logo

XBISPDR S&P Biotech ETF

$132.18
$0.56
(0.42%)
Overnight
Updated: 01:54 AM EDT·Prev Close $132.74
Vol10.18M
52W High$139.19
52W Low$80.90
34

Bearish Sentiment

How do you feel about XBI?

News
all
press releases
Why Is SMMT Stock Tumbling Today?
Summit announced a common stock offering, with underwriters having a 30-day option to purchase up to an additional $75 million of shares.
Stocktwits
News Placeholder
More News
News Placeholder
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.
Stocktwits
News Placeholder
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026
Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.
Stocktwits
News Placeholder
VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda
The Fast Track designation is designed to help promising medicines for serious diseases reach patients faster by allowing more frequent contact with regulators and potentially quicker review.
Stocktwits
News Placeholder
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’
CFO said at a conference that profitability is “right around the corner,” though the company is waiting for more top-line certainty before formal guidance.
Stocktwits
News Placeholder
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside
Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the third quarter.
Stocktwits
News Placeholder
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?
The company reported three deaths in the trial, though none were associated with its experimental drug gedatolisib.
Stocktwits
News Placeholder
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside
The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States.
Stocktwits
News Placeholder
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study
Oncolytics Biotech said preclinical data showed its experimental immunotherapy produced stronger anti-tumor effects in combination therapy, supporting future studies in pancreatic and colorectal cancers.
Stocktwits
News Placeholder
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Smart Beta ETF report for XBI
Zacks
<
1
2
...
>

Advertisement|Remove ads.